Introduction
Globally, melanoma is estimated to affect 200 000 individuals annually, and the highest incidence is reported in Australia [1] . With a median age of onset of 60 years, melanoma affects young and middle-aged adults disproportionately compared with other solid tumors [2] . When population-based mortality indicators, such as years of life lost, are considered as a measure of the impact of a disease on society, melanoma is among the top four malignancies in the USA [3] .
More than 90% of primary melanomas are diagnosed before evidence of distant metastasis and are potentially curable with adequate surgical treatment [4] . In the 2009 American Joint Committee on Cancer (AJCC) staging system for melanoma, 5-year survival was reported to be 95% for patients with stage I disease, 68% for stage II disease, and ranged from 80 to 42% for stages IIIA to IIIC, respectively [5] . Early detection of recurrent melanoma when it is amenable to treatment is important because it is believed to result in improved overall survival outcomes. Approximately 50% of all first recurrences are in the regional lymph nodes, 20% are local/regional recurrences, which include satellite and in-transit metastases, and 30% are at distant sites [6] [7] [8] [9] . For all patients with melanoma, the risk of first recurrence is the highest during the first 2 to 4 years after excision, but a small risk of death from recurrence remains even after 10 years [10] [11] [12] [13] . In addition, an estimated 1-8% of patients eventually develop a second primary melanoma [14] [15] [16] [17] [18] [19] [20] .
It has been reported that patients often detect their own recurrences, which calls into question the need for physician-directed surveillance and routine diagnostic imaging [21, 22] . However, one of the few prospective follow-up studies, by Garbe et al. [23] , showed that imaging, particularly sonography of the regional lymph nodes, detected a significant proportion of early recurrences in patients with stage I and II melanoma.
The increasing number of melanoma survivors and the increasing costs of healthcare mandate the development of practice guidelines for the surveillance of patients with melanoma [22, [24] [25] [26] [27] . We systematically examined the current body of literature and consensus guidelines to determine the variation in clinical practice patterns with respect to the stage-specific surveillance of melanoma patients by country and physician specialty.
Methods
The Scopus, PubMed, and Cochrane Library databases were searched for articles published between January 1970 and October 2011 on the surveillance of patients with melanoma. Search terms were 'post-treatment melanoma surveillance'; 'melanoma follow-up'; 'evidence-based follow-up' + 'melanoma'; 'evidence-based melanoma surveillance'; 'melanoma' + 'outcomes'; 'outcomes' + 'melanoma' + 'evidence-based follow-up'; and 'outcomes' + 'melanoma' + 'surveillance'. A total of 8315 articles were identified initially (Fig. 1 ). Articles were imported into Endnote X2.0 (Build 3210, Thomson Corporation, Stamford, Connecticut, USA), and duplicate entries were identified and deleted (n = 1054 articles).
In the second phase of the review, abstracts were reviewed for inclusion and exclusion criteria. Articles were excluded if they pertained only to patients with stage IV disease (n = 598) or patients receiving palliative or hospice care (n = 737); were not available in English translation (n = 16); or reported the primary outcomes of a clinical trial on the basis of treatment (n = 1074). The remaining 4820 articles were examined to determine whether the primary focus was on melanoma surveillance; articles that focused on staging (n = 4307), short-term postoperative follow-up (n = 83) or follow-up during systemic therapy (n = 326) were also excluded. The remaining 104 articles were included in this review. Fortyfour of the 104 articles reported patient-level observations. The other 60 articles reported surveillance practices but did not include patient-level data; these articles included reviews, expert opinion articles, and articles presenting specific recommendations related to particular imaging or laboratory evaluations.
Specific recommendations related to surveillance interval and surveillance examinations were extracted from each article and stratified according to the country of origin and, when reported, physician specialty. Country of origin Articles identified from initial search of MEDLINE, Scopus, and Cochrane Library databases n = 8315
Articles with defined surveillance intervals n = 43
Articles without defined surveillance intervals (e.g. reviews, cost studies, articles presenting recommendations on diagnostic imaging or laboratory evaluations) n = 61 was defined as the location of the corresponding author at the time of publication. In addition, a subset analysis was carried out of articles that had as their primary focus a comparison of surveillance practices among physician specialties.
Bandolier's evidence-based evaluation system for systematic reviews was used to assign the level of evidence for each article [28] (Table 1) . Each article was categorized independently and scored by two authors (K.D.C. and J.N.C.). Quality score discrepancies were resolved by consultation between these two authors.
Results

Studies reporting patient-level data
A total of 43 articles from 11 countries (Australia, Belgium, Canada, Denmark, England, France, Germany, Korea, the Netherlands, Switzerland, and the USA) and four physician specialties (primary care, dermatology, medical oncology, and surgical oncology) reported patient-level data for the surveillance of patients with invasive melanoma ( Table 2) . As only one article included patients with melanoma in situ, these patients were included in this summary [59] . In these 43 articles, a total of 150 829 patients were followed from 6 months to 36 years. The majority of the studies (n = 34) were retrospective; four were prospective nonrandomized studies [19, 23, 36, 52] ; three were cross-sectional interviews or survey studies [30, 35, 56] ; and one was a systematic review [44] . One article reported surveillance recommendations on the basis of a randomized trial, which was carried out with the primary objective of comparing the efficacy of immediate discharge to general practitioners versus ongoing surveillance by an oncologist [35] . The other study was a mixed-methods study (retrospective and cross-sectional interview) [43] . Only a relatively small number of retrospective studies examined the benefits of specific follow-up strategies [9, 22, 25, 27, 36, 40, 41, 60] . A single randomized, controlled trial was identified that included melanoma surveillance outcomes on the basis of physician specialty [35] .
Surveillance practices
Surveillance recommendations varied according to the disease stage, country of origin, and physician specialty.
Variations were related to the frequency of examination and the use of diagnostic imaging and laboratory tests. Questions were also raised for the need for any follow-up for patients with fully resected melanoma [29, 36, 61] ; however, some authors noted the increased risk for second primary melanomas in patients with an initial diagnosis of cutaneous melanoma and emphasized the importance of consistent follow-up [15, 17] . The only area of consensus was the importance of self-examination in the intervals between regular follow-up appointments.
Stage-specific surveillance recommendations by country for years 1 to 5 after the initial surgery are summarized in Table 3 . It is noteworthy that consensus documents did not exist for several countries and articles included in the previously reported systematic review did not include specific guidelines for follow-up of stage I-III disease and are therefore not included in Table 3 [24, 46, 53, [79] [80] [81] . Significant differences were found in the surveillance practices among countries ( Table 3 ). The most significant differences were found with respect to surveillance intervals following the treatment of stage I disease: the recommended frequency of visits ranged from one to six visits per year during the first 2 years after treatment. In a recent update of surveillance guidelines from Switzerland (2011) [77] , clinical examination two times per year was recommended for patients with stage I disease, whereas previously, four visits per year had been recommended [77, 78] . For patients with all stages of disease, the UK had the most intensive recommendations for imaging and laboratory evaluations, whereas the Netherlands had the most minimalist approach to testing ( Table 3) . The UK was the only country to recommend ongoing medical photography throughout the course of care. The Netherlands was the only country to recommend examination alone, with no diagnostic imaging nor laboratory evaluations. There was consensus across all countries on the need for self-examination by all patients, as well as agreement that patients with high-risk stage III disease require regular clinical examinations.
Stage-specific surveillance recommendations by physician specialty for years 1 to 5 after initial surgery are summarized in Table 4 . This analysis was based on the small subset of articles (n = 14) that included a comparison of surveillance practices by physician specialty. The recommendations for both surveillance intervals and diagnostic imaging and laboratory evaluations varied by specialty [26, 35, 50, 79, [82] [83] [84] [85] [86] 89] . The greatest variation was observed with respect to the recommended frequency of follow-up visits for patients with stage I disease, which ranged from two to four times per year. In addition to variable stage-specific recommendations [90] , one study reported a need to evaluate patients differently on the basis of race as lower 10-year survival and a higher risk of recurrence have been found in African American melanoma patients compared with White patients presenting with similar stages of disease [91, 92] . Stage-specific recommendations on the frequency of follow-up visits more than 5 years after initial surgery, by country and physician specialty, are summarized in Table 5 . There was a general consensus among countries and specialties for annual surveillance. One exception was the UK recommendation that follow-up after 5 years be considered only on an as-needed basis.
Discussion
This systematic review highlights the significant worldwide variation in stage-specific surveillance recommendations for melanoma patients with respect to both the frequency of surveillance visits and routine diagnostic imaging and laboratory evaluations during the first 5 years after treatment. Self-examination was a universal recommendation from every country [21, 29, 39, 47, 56, 61, 62, 64, 65, [75] [76] [77] [78] 93] and by all practitioner specialties [49, 50, 64, 66, 82, 83, [85] [86] [87] [88] . Surveillance recommendations varied the greatest for patients with stage I disease. Recommended imaging and laboratory evaluations were most intense in the UK and most minimalist in the Netherlands. Although general practitioners did not recommend routine laboratory nor imaging tests for surveillance, all other specialties utilized both in their surveillance practice.
A single randomized, controlled trial was identified that included melanoma surveillance outcomes on the basis of physician specialty [35] . In this trial, the efficacy of immediate discharge to a general practitioner for continued surveillance versus continued surveillance by a physician in an outpatient hospital setting was evaluated [35] . However, this study included patients CBC, complete blood cell count; CT, computed tomography. Table 4 Stage-specific surveillance guidelines by physician specialty during years 1 to 5 General practitioner [35, 50, [82] [83] [84] [85] [86] Dermatologist [64, 87, 88] Medical oncologist [66, 87] Surgical oncologist [49, 75] with various malignancies, including colorectal, gastric, pancreaticobiliary, head and neck, and skin cancers, as well as general surgical patients. Melanoma patients represented only a small subset of those included in the study. Patients who were randomized to receive care by general practitioners reported reduced travel time and lower associated costs as well as higher satisfaction. The authors found that the key contribution of immediate discharge from oncology care was the ability for oncologists to have more time to dedicate to new patients. The investigators concluded from their study that although surveillance in the general practice setting may be effective for some patients with low-stage, completely resected disease, those with more advanced disease undergoing more extensive surgical treatments were better served by ongoing surveillance in the clinical oncology setting.
Since the completion of the systematic review, an important article by Turner et al. [94] has been published examining the frequency of follow-up for melanoma patients. The objective of the study was to develop evidence-based guidelines for stage I and II patients. On the basis of a cohort of 3081 melanoma patients, 229 of every 1000 patients were observed to have recurrent melanoma and 61 developed a new primary in 10 years.
Using these results to model the delay in diagnosis on the basis of two different surveillance schedules, it was found that there was only a minimal delay in the diagnosis of recurrence associated with a reduced follow-up schedule of two visits per year for 2 years, followed by annual visits for years 3 through 10 compared with two visits per year for 5 years, followed by annual visits [94] . The study concluded that the minimal delay in the diagnosis of recurrence may not warrant the expense of added followup visits.
These findings are in agreement with those of a previous review of melanoma surveillance guidelines published in 2010 by Leiter et al. [52] , in which the authors reported that surveillance remains a controversial issue despite consensus on melanoma surgical treatment. Leiter et al. [95] have reported that the follow-up frequency for melanoma patients ranged from annually to every 3 months for a minimum of 5 years. In another report by Francken et al. [44] , the authors reported that only clinical examination and medical history are cost-effective tools for the detection of recurrences. An additional systematic review that evaluated country-specific differences did not arrive at any conclusive findings and limited country inclusion to the USA, Australia/New Zealand, and Germany [96] . With respect to surveillance imaging, lymph node sonography has been found to be a promising modality for the early detection of regional nodal recurrence, but survival benefits have not been shown [80, 81, 97, 98] . However, the results of sonography have been shown to be highly operator dependent, indicating that there may be significant variability in sensitivity when widely adopted in clinical practice.
In an attempt to provide data to inform future surveillance guidelines, our group has previously reported the stage-specific conditional survival outcomes in melanoma patients [11, 12] . Conditional survival represents the probability that a cancer patient will survive an additional year, given that he or she has already survived a given number of years. Using the nationwide surveillance, epidemiology, and end results database, we calculated conditional survival for patients with stage I, II, III, and IV melanoma. Conditional survival was relatively stable over time for stage I patients, at 97%, but for patients with more advanced disease, conditional survival was lower at the time of diagnosis and improved over time (Table 6 ) [12] . For example, at the time of diagnosis, a patient presenting with stage IV melanoma was estimated to have a 5-year disease-free survival of only 19%; however, for patients with stage IV disease who survived to 5 years, conditional survival for the following year was estimated to be 84%. A separate analysis of conditional survival outcomes for patients with substages of stage III melanoma patients was also carried out using our institutional melanoma database [11] . In this analysis, there was also a notable increase in conditional survival over time for these patients, which supports recommendations for increasing the surveillance interval, particularly beyond year 3, when the number of recurrences decreases over time.
In addition to the limitation that the majority of the studies in this systematic review were retrospective, many of the studies reported short follow-up times, and several studies that evaluated recurrences in patients beyond 5 years did not specify whether the patients were being examined at regular follow-up intervals or chose to return to surveillance because of a symptom or a new lesion [13, 99] . Another consideration is that the majority of the studies were carried out in the 1990s, before the widespread adoption of sentinel lymph node biopsy for the pathologic staging of regional lymph nodes and before the availability of contemporary diagnostic imaging. As a result of stage migration related to both sentinel lymph node biopsy and improved imaging, contemporary patients with stage II disease who are documented to be free of micrometastatic nodal disease are known to have more favorable outcomes than reported previously and may be more appropriately followed at less frequent intervals or with less testing. Although there is an increasing prevalence of melanoma in situ, surveillance practices for these patients have not been addressed adequately and are not included in the current review. In a recent population-based study, Mocellin et al. [100] reported that although patients with melanoma in situ have overall relative survival equal to the general population, ongoing surveillance is recommended because these patients are known to be more likely to develop additional primary melanomas. Publication bias should be considered in the context of all systematic reviews; it is possible that studies linking surveillance to poorer outcomes are less likely to be reported in the literature.
A number of studies have reported on surveillance strategies and their associated costs [24, 45, 55, 97, [101] [102] [103] . Although cost should not be the primary consideration in the development of surveillance recommendations, they should be considered. However, it is challenging to make international comparisons, given the differing healthcare systems and how these systems may influence decisions about whether a physician visit or test should be part of routine screening. It is evident that the majority of patients with melanoma recurrence are either selfdetected or detected during clinical examination, which calls into question the need for routine imaging and laboratory assessment [23, 24, 29, 48, 65, 104] . Furthermore, the use of specific imaging tests has been scrutinized and it has been reported that many diagnostic imaging examinations are not beneficial in detecting early melanoma recurrence [103, 105] . The impact of frequent, intensive follow-up screening on quality of life should also be considered as it has been documented that increased screening can result in patient-reported stress and anxiety [86, 106, 107] .
In a cost-comparison study of various surveillance strategies, Leiter et al. [97] reported that the estimated cost to detect one recurrence in a patient with stage I melanoma was $38 574 (h13 388) because the majority of patients who complete lifelong follow-up for stage I melanoma do not have a recurrence. Given the high cost and low rate of detection of recurrence, particularly in patients with early disease, the authors suggested that surveillance should be tailored or risk-adapted to reduce costs in patients with stage I disease while increasing surveillance with imaging and related expenditures in patients with higher risk, stage III disease [47] . Such an approach would increase the detection of early treatable recurrences in higher-risk patients [97] . An additional study that examined the costeffectiveness of surveillance noted that routine lymph node sonography detected an additional 17% (stage I) and 22% (stage II) of early recurrences, which, at a cost of approximately $187 per evaluation, resulted in a total cost per metastasis detected of $10 942 for stage I disease, $5 804 for stage II disease, and $4364 for stage III disease [45] . Although it is not advocated that costs be the primary consideration in the surveillance of cancer patients, costly tests should be evaluated before their adoption, and those with excellent positive predictive values may provide the best value [105] .
Despite the prevalence of melanoma survivors and the demonstrated benefit of detection of early recurrences [6, 23] , there continues to be a lack of universal guidelines for stage-specific surveillance of melanoma patients. Randomized trials of more intensive versus less intensive follow-up are difficult to conduct and require long-term follow-up, which is expensive. As a result, clinical practice is based primarily on retrospective reviews and traditional practices, resulting in wide variations [44, 90, 71, 108] . Currently, there is little evidence documenting that intensive surveillance practices are associated with increased survival. To establish evidencebased guidelines, prospective randomized-controlled trials or stage-specific decision models are required that evaluate patients from the point of designation as disease free throughout the course of their life. 
